Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,398 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SOC Clear all
Recruiting No phase listed Observational

Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)

NCT06434337
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Novel point-of-care diagnostic test for detecting HPV ("Rice HPV test")
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 17, 2026, 11:08 AM EDT
Completed No phase listed Observational

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

NCT05841030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
No Intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Homewood, Alabama • California City, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 17, 2026, 11:08 AM EDT
Completed Not applicable Interventional

Ipsilateral Peripheral Intravenous Access Procedures (The iPIVAP Study)

NCT04570722
View directory record Official record
Conditions
Breast Cancer, Melanoma, Thoracic Cancer, Lymphedema of Upper Arm
Interventions
Ipsilateral peripheral IV insertion
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 17, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Results available

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

NCT02293837
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM, T1D
Interventions
Tocilizumab (TCZ), Placebo, Standard of Care
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 17 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 17, 2026, 11:08 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )

NCT06939036
View directory record Official record
Conditions
Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
Interventions
225Ac-SSO110 + SoC, Atezolizumab, Durvalumab, Avelumab, Pembrolizumab, Retifanlimab
Drug
Lead sponsor
Ariceum Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Miami, Florida • Louisville, Kentucky • Glen Burnie, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 11:08 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

REFLECTION: A Clinical Practice Learning Program for Galleri®

NCT05205967
View directory record Official record
Conditions
Early Detection of Cancer, Cancer
Interventions
MCED, SOC
Other
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
22 Years and older
Enrollment
14,633 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
16
States / cities
Scottsdale, Arizona • Burbank, California • Fullerton, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 17, 2026, 11:08 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 17, 2026, 11:08 AM EDT
Recruiting Phase 3 Interventional

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

NCT04678154
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Standard of care, Vancomycin and Tobramycin
Drug
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
31
States / cities
Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 17, 2026, 11:08 AM EDT
Completed Not applicable Interventional

Increase HIV Testing Among Truck Drivers and Female Sex Workers in Kenya Through Offering HIV Self-Testing

NCT03662165
View directory record Official record
Conditions
HIV Testing
Interventions
Intervention, Enhanced Standard of Care, Traditional Standard of Care
Behavioral
Lead sponsor
City University of New York, School of Public Health
Other
Eligibility
18 Years and older
Enrollment
4,458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 17, 2026, 11:08 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

NCT03393000
View directory record Official record
Conditions
Glioblastoma
Interventions
Trans Sodium Crocetinate plus SOC, Standard of Care (SOC)
Drug · Other
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Irvine, California • Redwood City, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 17, 2026, 11:08 AM EDT
Recruiting Not applicable Interventional

Accelerated Pulmonary Rehabilitation in the Preoperative Period

NCT06432972
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Lung Cancer
Interventions
Pulmonary Rehab
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 11:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

NCT06839456
View directory record Official record
Conditions
Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia, MDS (Myelodysplastic Syndrome), Relapsed Non-Hodgkin Lymphoma, Acquired Aplastic Anemia, Inherited BMF Syndrome, Immunodeficiency, Primary Immune Regulatory Disorder, Hemoglobinopathies, Bone Marrow Failure, Inborn Errors of Metabolism, HLH
Interventions
Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3, Phase 2 Maximum Tolerated Dose determined in Phase 1, Phase 2 Established Dose from prior study, NCT03810196
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 17, 2026, 11:08 AM EDT
Recruiting Early Phase 1 Interventional

Impact of Intraoperative ICG on Functional Outc in RARP

NCT06446648
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
ICG
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 17, 2026, 11:08 AM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 17, 2026, 11:08 AM EDT
Completed Not applicable Interventional

Guided IMagery and Patient Satisfaction (GIMPS) Following Urogynecological Surgery

NCT02165280
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Guided IMagery (GIM)
Behavioral
Lead sponsor
Loyola University
Other
Eligibility
21 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 17, 2026, 11:08 AM EDT
Not listed Not applicable Interventional

Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs

NCT06600724
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic, Foot Ulcer
Interventions
Standard of Care, EPIEFFECT, EPIXPRESS
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 11:08 AM EDT
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 11:08 AM EDT
Withdrawn Phase 3 Interventional

Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF

NCT04592380
View directory record Official record
Conditions
Dyspnea, Hypertension, Acute Heart Failure
Interventions
Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
9
States / cities
Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 17, 2026, 11:08 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

NCT00691015
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
rituximab, busulfan, carmustine, cyclophosphamide, cytarabine, etoposide, fludarabine phosphate, melphalan, total body irradiation (TBI), anti-thymocyte globulin IV
Biological · Drug · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 17, 2026, 11:08 AM EDT
Recruiting Not applicable Interventional

Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia

NCT06982820
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Prism Training
Device
Lead sponsor
GrayMatters Health Ltd.
Industry
Eligibility
22 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Providence, Rhode Island • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 17, 2026, 11:08 AM EDT
Not yet recruiting No phase listed Observational

Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control

NCT06783868
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Catheter Ablation, Market-approved AVNB, OAC and AAD
Device · Drug
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Overland Park, Kansas • Independence, Missouri • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 17, 2026, 11:08 AM EDT
Recruiting Phase 3 Interventional

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07355218
View directory record Official record
Conditions
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 11:08 AM EDT
Completed Phase 1 Interventional

Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients

NCT01802970
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Anakinra plus Standard of Care
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 17, 2026, 11:08 AM EDT
Recruiting Not applicable Interventional

HOPE-BP 2.0: Evaluating the Optimal Duration of Postpartum Remote Blood Pressure Monitoring

NCT07204756
View directory record Official record
Conditions
Postpartum, Hypertension, Hypertensive Disorder of Pregnancy
Interventions
2-Week Home Monitoring, 6-Week Home Monitoring
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 17, 2026, 11:08 AM EDT